Serum-derived Bovine Immunoglobulin Effect on Mucositis
A Randomized, Placebo-Controlled, Pilot Study of Serum-Derived Bovine Immunoglobulin/Protein Isolate to Manage Mucositis in Patients Undergoing Treatment for Head, Neck, or Lung Cancer
Sponsor: MercyOne Des Moines Medical Center
Terminated
Recruitment slower than anticipated
Other terminated trials from MercyOne Des Moines Medical Center
More terminations from MercyOne Des Moines Medical Center
Other Mucositis trials with similar outcome
This PHASE2 trial investigates Mucositis and is currently terminated or withdrawn. MercyOne Des Moines Medical Center leads this study, which shows 8 recorded versions since 2020 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Feb 2023 — Jul 2024 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
May 2022 — Feb 2023 [monthly]
Recruiting PHASE2
-
Mar 2021 — May 2022 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2
-
Mar 2020 — Jan 2021 [monthly]
Recruiting PHASE2
-
Feb 2020 — Mar 2020 [monthly]
Recruiting PHASE2
First recorded
Jan 2020
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- MercyOne Des Moines Medical Center
For direct contact, visit the study record on ClinicalTrials.gov .